Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

Benzinga Newsdesk www.benzinga.com Positive 50.2%

Neg 0% Neu 0% Pos 50.2%

Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $20.